Display options
Cite
Sun H, Scott DO. Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design. ACS Med Chem Lett. 2011;2(8):638-643doi: 10.1021/ml200117z.
Sun, H., & Scott, D. O. (2011). Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design. ACS medicinal chemistry letters, 2(8), 638-643. https://doi.org/10.1021/ml200117z
Sun, Hao, and Scott, Dennis O. "Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design." ACS medicinal chemistry letters vol. 2,8 (2011): 638-643. doi: https://doi.org/10.1021/ml200117z
Sun H, Scott DO. Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design. ACS Med Chem Lett. 2011 Aug 11;2(8):638-643. doi: 10.1021/ml200117z. Epub 2011 Jun 18. PMID: 21841964; PMCID: PMC3155282.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2011 Aug 11;2(8):638-643. doi: 10.1021/ml200117z. Epub 2011 Jun 18.

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design.

ACS medicinal chemistry letters

Hao Sun, Dennis O Scott

Affiliations

  1. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc. , Groton, Connecticut 06340, United States.

PMID: 21841964 PMCID: PMC3155282 DOI: 10.1021/ml200117z

Abstract

4-Aminopiperidines are a variety of therapeutic agents that are extensively metabolized by cytochrome P450s with CYP3A4 as a major isoform catalyzing their N-dealkylation reaction. However, its catalytic mechanism has not been fully elucidated in a molecular interaction level. Here, we applied theoretical approaches including the molecular mechanics-based docking to study the binding patterns and quantum mechanics-based reactivity calculations. They were supported by the experimental human liver microsomal clearance and P450 isoform phenotyping data. Our results herein suggested that the molecular interactions between substrates and CYP3A4 active site residues are essential for the N-dealkylation of 4-aminopiperidines. We also found that the serine 119 residue of CYP3A4 may serve as a key hydrogen-bonding partner to interact with the 4-amino groups of the studied drugs. The reactivity of the side chain α-carbon hydrogens drives the direction of catalysis as well. As a result, structure-based drug design approaches look promising to guide drug discovery programs into the optimized drug metabolism space.

References

  1. Xenobiotica. 1980 Mar;10(3):211-8 - PubMed
  2. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3177-82 - PubMed
  3. Drug Metab Dispos. 1981 Sep-Oct;9(5):442-8 - PubMed
  4. Br J Clin Pharmacol. 2004 Sep;58(3):277-87 - PubMed
  5. Br J Clin Pharmacol. 2001 Feb;51(2):133-42 - PubMed
  6. Xenobiotica. 1990 Dec;20(12):1357-67 - PubMed
  7. J Pharmacol Exp Ther. 1998 May;285(2):428-37 - PubMed
  8. J Pharmacol Exp Ther. 2001 Aug;298(2):508-20 - PubMed
  9. Drug Metab Dispos. 1996 Sep;24(9):932-9 - PubMed
  10. Chem Biol Drug Des. 2010 Jan;75(1):3-17 - PubMed
  11. Biochemistry. 2010 Oct 19;49(41):9011-9 - PubMed
  12. Forensic Sci Int. 2010 Feb 25;195(1-3):68-72 - PubMed
  13. Eur J Drug Metab Pharmacokinet. 1983 Oct-Dec;8(4):335-49 - PubMed
  14. Eur J Drug Metab Pharmacokinet. 1994 Jul-Sep;19(3):209-17 - PubMed
  15. Mol Pharmacol. 2002 Mar;61(3):495-506 - PubMed
  16. Cancer Sci. 2010 Oct;101(10):2193-9 - PubMed
  17. Psychopharmacology (Berl). 1994 Dec;116(4):457-63 - PubMed
  18. Arzneimittelforschung. 1987 Jan;37(1):32-7 - PubMed

Publication Types